|
|
|
|
| |
| Name and Educational Degree: |
| Solleveld, Henk, DVM, PhD |
| Veterinary Pathology (Dutch Registry) and Laboratory Animal/Toxicologic Pathologist (Dutch Registry) |
DVM (cum laude): University of Utrecht, Utrecht, The Netherlands, 1976 PhD (cum laude): University of Utrecht, Utrecht, The Netherlands, 1981 |
10 Kiloran Wynd
Glenmoore, PA 19343
USA |
Henk Solleveld is a Preclinical Pharmaceutical Executive with over 20 years of experience in the Discovery and Development arenas within the pharmaceutical industry. His experience cuts across every facet of the R & D process. He has led pathology and toxicology groups, discovery DMPK and liaised in the discovery organization with all preclinical departments, viz., safety assessment, development DMPK and chemical and pharmaceutical development. Henk has demonstrated adaptability and multitasking capabilities in SmithKline Beecham (SB) and GlaxoSmithKline (GSK) as he has managed successfully a portfolio of more than 15 programs/projects within Safety Assessment as well as in the Discovery organization, including cardiovascular, urology, metabolism, CNS, anti-inflammatory, anti-cancer and anti-viral compounds. He had direct responsibility for the preclinical sections of 2 NDAs/MAAs (Coreg and Requip) and was closely involved in the Regulatory Submissions and discussions for Kytril, Famvir, Teveten, Topotecan and Avandia. Involvement in leadership roles within R&D, in which interactions across multiple interfaces and teamwork are crucial elements, consisted of preclinical representation on the Worldwide Labelling Committee, Cardiovascular Therapeutic area team, Preclinical Executive Committee, Safety Assessment Executive Committee, member of the Predictive Toxicology Board, Chair of the Development Heads Committee, ad hoc Member of Global Clinical Safety Board, and Executive on the Cardiovascular and Urology Center of Excellence for Drug Discovery.
Most recently Henk was Transnational Vice-President and Head of Preclinical Drug Discovery in the Cardiovascular-Urology Center of Excellence for Drug Discovery (CVU CEDD) with staff in US, UK and France (2000-2008). He was responsible for all discovery DMPK activities from tractable hit to candidate selection and for preclinical development activities up to Proof of Concept in collaboration with leaders of Toxicology, development DMPK, Pharmaceutical Development and Chemical Development. He played a key role in filing INDs for the CVU CEDD. Prior to the formation of GSK, Henk was Transnational Group Director of Pathology and Regulatory Toxicology with operations in the US and UK and played a key leadership role as Chair of the Development Department Heads Committee. This was a committee of non-clinical department directors, including discovery. The group was charged with developing and executing the early project plan to support Phase I/II and to accelerate the early timeline. As Chair of this committee, broad-based skills in identifying and resolving development issues were critical elements. Further, Henk earned both his Doctor of Veterinary Medicine (cum laude) degree and his PhD (cum laude) from the State University of Utrecht, Utrecht, Netherlands in 1976 and 1981, respectively. He is board certified (Dutch registry) in laboratory animal pathology and veterinary pathology. He has widely published (about 130 manuscripts, book chapters and abstracts) in the areas of pathology and toxicology and was editor of 2 books. Prior to joining SB in 1987 as an Assistant Director of Safety Evaluation, Dr. Solleveld worked as a veterinary research pathologist at TNO, Institute for Experimental Gerontology in The Netherlands, and also at the National Toxicology Program, National Institute of Environmental and Health Sciences, Research Triangle Park, NC. In 1984, he received a U.S. DHHS Award in recognition and appreciation of special achievement. |
| 2000 - 2008: Transnational Vice-President and Head, Preclinical Drug Discovery, Cardiovascular/Urogenital Center of Excellence Drug Discovery, GSK 1998 -2000: Transnational Group Director, Investigative Pathology & Regulatory Toxicology, SmithKline Beecham |
<< Back to Index of Consultants
|
|
|
|
|
|
|
